Name | N-tert-butyl-3-[[5-methyl-2-[4-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]benzenesulfonamide |
---|---|
Synonyms |
EX-8668
RS0111 3-[(5-Methyl-2-{[4-(4-morpholinylmethyl)phenyl]amino}-4-pyrimidinyl)amino]-N-(2-methyl-2-propanyl)benzenesulfonamide Benzenesulfonamide,N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino] Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- N-tert-butyl-3-(5-methyl-2-(4-(morpholinomethyl)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide TG-46 |
Description | JAK-IN-35 (compound TG46) is a JAK2 inhibitor that canb be used in cancer research[1]. |
---|---|
Related Catalog | |
References |
[1]. Wenge Zhu, et al. Combination therapy for treating cancer. Patent WO2018187485A1. |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 687.5±65.0 °C at 760 mmHg |
Molecular Formula | C26H34N6O3S |
Molecular Weight | 510.652 |
Flash Point | 369.6±34.3 °C |
Exact Mass | 510.241302 |
PSA | 120.09000 |
LogP | 1.83 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.621 |